Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents
SME3110 (Fluvoxamine Maleate) in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placeb-controlled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Chiba prefecture, Japan
- S114.3.117 Kohnodai Hospital, National Center of N
-
Fukuoka prefecture, Japan
- S114.3.117 Fukuoka University Hospital
-
Fukuoka prefecture, Japan
- S114.3.117 Hatakeyama Clinic
-
Fukuoka prefecture, Japan
- S114.3.117 Kaname Clinic
-
Fukuoka prefecture, Japan
- S114.3.117 Kashi shinryo Clinic
-
Fukuoka prefecture, Japan
- S114.3.117 Kashii Sanatorium
-
Fukuoka prefecture, Japan
- S114.3.117 Kyushu University Hospital
-
Fukuoka prefecture, Japan
- S114.3.117 Shiranui Hospital
-
Fukuoka prefecture, Japan
- S114.3.117 Sugahara Tenjin Hospital
-
Hiroshima prefecture, Japan
- S114.3.117 Hiroshima-city Funairi Hospital
-
Hokkaido prefecture, Japan
- S114.3.117 Goryokai Hospital
-
Hyogo prefecture, Japan
- S114.3.117 Kobe University Hospital
-
Kagawa prefecture, Japan
- S114.3.117 National Hospital Organization Kagawa C
-
Kanagawa Prefecture, Japan
- S114.3.117 Yokohama City University Hospital
-
Kumamoto prefecture, Japan
- S114.3.117 National Hospital Organization Kikuti N
-
Kyoto prefecture, Japan
- S114.3.117 Kyoto University Hospital
-
Mie prefecuture, Japan
- S114.3.117 National Hospital Organization Sakakiba
-
Nagano prefecture, Japan
- S114.3.117 Shinshu University Hospital
-
Nagoya prefecture, Japan
- S114.3.117 Aichi Children's Health and Medical Cen
-
Nagoya prefecture, Japan
- S114.3.117 Nagoya Mental Clinic
-
Nara prefecture, Japan
- S114.3.117 Nara Medical University Hospital
-
Osaka prefecture, Japan
- S114.3.117 Kansai Medical University Takii Hospita
-
Osaka prefecture, Japan
- S114.3.117 Kusube Clinic
-
Osaka prefecture, Japan
- S114.3.117 Yasuhara Children's Clinic
-
Tokushima prefecture, Japan
- S114.3.117 Tokushima University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: P
|
Placebo
|
|
Experimental: F
|
Test product: Fluvoxamine maleate 25mg tablet.
In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime.
In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the time of onset of 50% decrease from baseline in the Japanese Version of the Structured Interview Guide for the Hamilton Depression Rating Scale (JSIGH-D) 17-item total score
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Clinical Global Impression(CGI) improvement at Week 8
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Toshiaki Yamaguchi, Solvay Pharmaceuticals
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Anti-Anxiety Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Fluvoxamine
Other Study ID Numbers
Other Study ID Numbers
- S114.3.117
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.